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Original Article
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Background: The optimal strategy of peri-procedural anticoagulation in patients undergoing permanent

cardiac device implantation is controversial. Our objective was to compare the major bleeding and
thromboembolic complications in patients managed with uninterrupted warfarin (UW) vs. interrupted
dabigatran (ID) during permanent pacemaker (PPM) or implantable cardioverter defibrillators (ICD)
implantation.
Methods: A retrospective cohort study of all eligible patients from July 2011 through January 2012 was

performed. UW was defined as patients who had maintained a therapeutic international normalized ratio
(INR) on the day of the procedure. ID was defined as stopping dabigatran ≥12 hours prior to the procedure
and then resuming after implantation. Major bleeding events included hemothorax, hemopericardium,
intracranial hemorrhage, gastrointestinal bleed, epistaxis, or pocket hematoma requiring surgical
intervention. Thromboembolic complications included stroke, transient ischemic attack, deep venous
thrombosis, pulmonary embolism, or arterial embolism.
Results: Of the 133 patients (73.4±11.0 years; 91 males) in the study, 86 received UW and 47 received ID.

One (1.2%) patient in the UW group sustained hemopericardium perioperatively and died. In comparison,
the ID patients had no complications. As compared to the ID group, the UW group had a higher median
CHADS2 score (2 vs. 3, P=0.04) and incidence of Grade 1 pocket hematoma (0% vs. 7%, P=0.09). Neither
group developed any thromboembolic complications.
Conclusions: Major bleeding rates were similar among UW and ID groups. Perioperative ID appears to be

a safe anticoagulation strategy for patients undergoing PPM or ICD implantation.
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Submitted Aug 26, 2015. Accepted for publication Sep 25, 2015.
doi: 10.3978/j.issn.2223-3652.2015.10.06
View this article at: http://dx.doi.org/10.3978/j.issn.2223-3652.2015.10.06

© Cardiovascular Diagnosis and Therapy. All rights reserved.

www.thecdt.org

Cardiovasc Diagn Ther 2016;6(1):3-9

4

Introduction
Approximately 176,000 patients receive permanent
pacemakers (PPM) or implantable cardioverter defibrillators
(ICD) annually in the USA (1). Of these, a significant
proportion receive chronic oral anticoagulation therapy
with warfarin for treatment of atrial fibrillation (2). As
such, an understanding of appropriate management of
anticoagulation in the context of device implantation is
crucial (3,4). Unfortunately, agreement on an optimal
perioperative strategy remains controversial.
In the last decade, various anticoagulation regimens
have been employed and respective outcomes compared
(3-8). Approaches are classified as either “interrupted” or
“continued” anticoagulation. Interrupted anticoagulation
places patients at higher risk for cardioembolic events,
but continued therapy may increase the risk of bleeding
complications such as pocket hematomas (5,6). A previously
proposed method based on ACC/AHA guidelines of
interrupted warfarin therapy with low molecular weight
heparin (LMWH) bridging has been abandoned in many
centers due to a concomitant high incidence of pocket
hematomas (6-9). Instead, uninterrupted warfarin (UW)
has become an accepted strategy as it has been linked to
reduced rates of bleeding complications and shorter hospital
stays (5,10-13).
However, the availability of newer anticoagulants such
as dabigatran brings the possibility of superior outcomes
for this patient population. The more predictable
pharmacological profiles of these new drugs allow for shortterm interruption that may potentially improve device
implantation safety by reducing bleeding complications.
Additionally, the ability to stop these drugs for a short
period of time before clot formation can occur may lead to
similar efficacy in regards to prevention of thromboembolic
adverse outcomes in high risk patients. However,
certain agents such as LMWH with short half-lives have
been linked to increased risk of pocket hematoma
development (4). This immediate post-operative risk
of increased bleeding is not as well-known with newer
anticoagulants such as dabigatran.
The RE-LY trial demonstrated superior efficacy of
dabigatran in the prevention of stroke and systemic
embolism, as well as similar rates of major bleeding when
compared to warfarin (14). There are few articles regarding
safety of perioperative anticoagulation with dabigatran
(15-18). In this retrospective study, we compared the safety
of UW to interrupted dabigatran (ID) in patients requiring

© Cardiovascular Diagnosis and Therapy. All rights reserved.

Madan et al. Warfarin vs . dabigatran in implantable cardiac devices

a PPM or ICD. We hypothesized that the risk of major
bleeding would be similar between UW and ID therapy and
the use of perioperative dabigatran in patients undergoing
device implantation would be a safe strategy.
Material and methods
Study design
This was a single center retrospective study comparing
major bleeding and thromboembolic events in patients who
underwent PPM or ICD placement with either UW or ID
therapy during a six-month period, July 2011 to January
2012, at Spectrum Health—Butterworth Hospital, a 989-bed
teaching hospital in West Michigan. Five experienced
cardiac electrophysiologists, who implant approximately
1,250 devices each year, performed all procedures. Patient
charts were reviewed systematically to obtain demographic,
clinical, and laboratory characteristics pre- and postprocedure. The study was approved by the hospital
institutional review board.
Inclusion/exclusion criteria
All patients who required a new device implantation or had
an existing device replaced and met the inclusion criteria
were included. Inclusion criteria included documented
diagnosis of atrial fibrillation and currently on chronic
anticoagulation with either warfarin or dabigatran. The
exclusion criteria included age <18 years, pregnancy,
history of mechanical heart valves, international normalized
ratio (INR) >4 and patients who switched therapy from
dabigatran to warfarin or vice versa in the perioperative
time period.
Clinical procedures
Perioperative anticoagulation protocols were based
on the clinical judgment of the attending cardiac
electrophysiologist. If a patient was in the UW cohort,
INR was checked the morning of the procedure to confirm
that the INR was <4. All patients in the ID group had nonvalvular atrial fibrillation, as well as a creatinine clearance
greater than 30 mL/min and had dabigatran held at least
12 hours prior to the procedure. Patients received a dose
of dabigatran at a mean time of 23.3 hours (range, 1291 hours) prior to the start of procedure and resumed
dosing at a mean time of 21.0 hours (range, 9-54 hours)
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after the procedure. PPM and ICD leads were placed under
fluoroscopic guidance. Leads were implanted through
the subclavian or axillary vein after administration of
prophylactic antibiotic and local anesthesia. Both active and
passive fixation leads were used for atrial and ventricular
leads.
Outcome variables and definitions
The primary outcome of the study was major bleeding
within one-month post procedure. Major bleeding was
defined as hemothorax, hemopericardium, intracranial
hemorrhage, gastrointestinal bleed, epistaxis, or pocket
hematoma requiring surgical intervention. Pocket
hematoma was defined as a palpable and visible soft mass
in the pacemaker pocket with or without the need for
evacuation. Pocket hematomas were graded 0 to 3 based
on severity. A pocket hematoma score of 0 described either
skin ecchymosis or minimal hematoma, whereas a score of
3 described a hematoma that required surgical evacuation.
Scores of 1 and 2 correlated to a hematoma size smaller
than or greater than the size of the generator, respectively.
All patients were followed up within 1-2 weeks post-procedure
for surgical site assessment in the electrophysiology
outpatient clinic or in the hospital. Thromboembolic
complications included stroke, transient ischemic attack,
deep venous thrombosis, pulmonary embolism, or arterial
embolism. All-cause mortality within 1-month postprocedure was obtained from patient charts and verified
using the social security death index.

5

The mean age of the sample was 73 years and the majority
of patients were males. Patients in the UW group had
significantly higher median CHADS2 scores than the ID
group. Notably, the prevalence of prior stroke or TIA was
over two-fold higher in the UW group than in the ID
cohort, although this was not a significant difference. With
regards to the other comorbidities, there were no significant
differences between the groups. Of note, mean INR on the
day of procedure in the UW group was 2.3±0.7 (Table 1).
Overall, 71 patients (53.4%) received a PPM while
62 (46.6%) had ICD placed. Among the UW cohort, 45
(52.3%) received a PPM and 41 (47.7%) received an ICD.
Of those patients who received an ICD in UW group, 23
(26.7%) had biventricular ICD. In the ID group, 26 (55.3%)
received a PPM and 21 (44.7%) received an ICD. Fourteen
patients (29.8%) in the ID cohort received biventricular
ICDs. Indications for implantation of the device are shown
in Table 2.
Among the 133 patients included in the study, there was
one major bleeding event, which occurred in the UW group
(Table 3). This was also the only patient who died within
one month of the procedure. The incidence of pocket
hematomas was higher in the UW group (7%) than in the
ID group (0%), but this was not statistically significant
(P=0.09). All pocket hematomas were identified as grade 1
and none required surgical evacuation or anticoagulation
cessation. Overall, there was no statistically significant
difference in thromboembolism and bleeding between the
UW and ID cohorts.
Discussion

Statistical analysis
Summary statistics were calculated. Continuous variables
are expressed as the mean ± SD, categorical data as
percentages, and the CHADS2 data as the median (range).
Differences among quantitative variables for the two groups
were determined using the t-test. Categorical variables were
analyzed using the Fisher’s Exact test. CHADS2 data were
compared using the Mann-Whitney test. Significance was
assessed at P<0.05. Statistical analyses were performed using
IBM SPSS Statistics version 20 (Armonk, NY, USA).
Results
A total of 133 patients met the inclusion criteria resulting
in 86 (64.7%) in the UW cohort and 47 (35.3%) in the
ID cohort. Baseline characteristics are shown in Table 1.

© Cardiovascular Diagnosis and Therapy. All rights reserved.

This study suggests that dabigatran use perioperatively
in patients requiring a PPM or ICD when compared to
continued anticoagulation with warfarin may lead to less
bleeding complications. Previous studies have demonstrated
a higher incidence of hemorrhagic events associated with
heparin bridging without warfarin reversal (19,20). A higher
incidence of hemorrhage associated with post-operative use
of heparin has also been described in the literature (6,7,21).
Cheng et al. showed that LMWH used post-operatively
causes an increased incidence of pocket hematoma (4).
Continued anticoagulation with UW has been shown to be
safer than heparin bridging in prior studies (5,10-13).
To date, few studies have investigated the safety and
efficacy of dabigatran in the perioperative period. Rowley
et al. performed a prospective observational study of
patients receiving dabigatran but only included 25 patients
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Table 1 Patient baseline characteristics
Characteristic

All patients [n=133]

Uninterrupted warfarin [n=86]

ICD [n=47]

P value

Age (years)*

73.4±11.0

73.0±11.6

74.0±9.7

0.63

Gender—male

68.4% [91]

67.4% [58]

70.2% [33]

0.85

Race—caucasians

97% [129]

95.3% [82]

100% [47]

0.30

29.2±6.2

28.9±6.1

29.8±6.5

0.46

BMI (kg/m2)*
CHADS2 score^

3 [0-6]

3 [1-6]

2 [0-5]

0.004

Stroke/TIA

21.1% [28]

25.6% [22]

12.8% [6]

0.12

Hypertension

80.5% [107]

82.6% [71]

76.6% [36]

0.49

CAD

51.9% [69]

55.8% [48]

44.7% [21]

0.28

DM

30.8% [41]

30.2% [26]

31.9% [15]

0.85

PE

3% [4]

4.7% [4]

0% [0]

0.30

6.8% [9]

9.3% [8]

2.1% [1]

0.16

0% [0]

0% [0]

0% [0]

>0.999

51.1% [68]

52.3% [45]

48.9% [23]

0.72

4.5% [6]

3.5% [3]

6.4% [3]

0.67

Previous PPM/ICD

31.6% [42]

34.9% [30]

25.5% [12]

0.33

Ejection fraction (%)*

40.7±16.7

39.3±17.0

44.1±15.7

0.11

Hemoglobin*

13.2±1.8

13.0±1.8

13.6±5.4

0.33

DVT
Epistaxis
Aspirin use
Clopidogrel use

Creatinine*
GFR*

1.2±0.6

1.3±0.8

1.1±0.3

0.14

48.5±13.6

47.3±14.0

51.0±12.9

0.13

INR*
@ Procedure

2.3±0.7

@ 1 Week

2.5±0.7

@ Complication

2.8±0.8

*, Data are shown as means±SD; ^, data are shown as median (range). The CHADS2 score is a measure of the risk of stroke in
which congestive heart failure, hypertension, an age of 75 years or older, and diabetes mellitus are each assigned 1 point and
previous stroke or transient ischemic attack is assigned 2 points; the score is calculated by summing all points for a given patient.
CAD, coronary artery disease; DM, diabetes mellitus; PE, pulmonary embolism; DVT, deep vein thrombosis; PPM, permanent
pacemaker; ICD, implantable cardioverter defibrillators; BUN, blood urea nitrogen; GFR, glomerular filtration rate; TIA, transient
ischemic attack.

Table 2 Indications for device implantation
Characteristic

All patients [%] [n=133]

Uninterrupted warfarin [%] [n=86]

Interrupted dabigatran [%] [n=47]

Indication
Bradycardia
Slow atrial fibrillation
RFA/permanent pacing

18 [24]
6 [8]

7 [6]

27.7 [13]
4.3 [2]

20.9 [18]

17 [8]

10.5 [9]

6.4 [3]

40.6 [54]

41.9 [36]

38.3 [18]

Mobitz type 2 AV block

3.0 [4]

3.5 [3]

2.1 [1]

Type 3 AV block

3.8 [5]

3.5 [3]

4.3 [2]

VT/VF
CHF req. biventricular device

19.5 [26]

12.8 [11]

9 [12]

AV, atrioventricular; CHF, congestive heart failure; RFA, radiofrequency ablation with permanent pacing; VF, ventricular fibrillation;
VT, ventricular tachycardia.

© Cardiovascular Diagnosis and Therapy. All rights reserved.
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Table 3 Perioperative bleeding and thromboembolic complications*
Characteristic

All patients [n=133]

Uninterrupted warfarin [n=86]

Interrupted dabigatran [n=47]

P value

0.8 [1]

1,2 [1]

0 [0]

P>0.999

0 [0]

0 [0]

0 [0]

P>0.999

0.8 [1]

1.2 [1]

0 [0]

P>0.999

ICH

0 [0]

0 [0]

0 [0]

P>0.999

GI Bleed

0 [0]

0 [0]

0 [0]

P>0.999

Epistaxis req. packing

0 [0]

0 [0]

0 [0]

P>0.999

Stroke/TIA

0 [0]

0 [0]

0 [0]

P>0.999

DVT

0 [0]

0 [0]

0 [0]

P>0.999

PE

0 [0]

0 [0]

0 [0]

P>0.999

Arterial embolism

0 [0]

0 [0]

0 [0]

P>0.999

4.5 [6]

7.0 [6]

0 [0]

0.8 [1]

1.2 [1]

0 [0]

Major complication
Major bleeding
Hemothorax
Hemopericardium

Thromboembolic

#

Minor complication

0.09

Mortality
1 month mortality

P>0.999

#

*, Perioperative time window was defined as 30 days post-implant; , all pocket hematomas, all less than the size of the generator.
DVT, deep venous thrombosis; GI, gastrointestinal; ICH, intracranial hemorrhage; PE, pulmonary embolism; TIA, transient ischemic
attack.

in their investigation (15). In concordance with results from
this study, there was no significant increase of thrombosis
or major bleeding complications. Healey et al. performed
a retrospective analysis of 4,591 patients from the RE-LY
study undergoing various invasive procedures who were
receiving anticoagulation therapy with either warfarin or
dabigatran (22). There was no significant difference in rates
of periprocedural major bleeding in various dabigatran
cohorts compared to warfarin. However, there was a large
range in dosing time of dabigatran pre- and post-procedure.
Similarly, we found no significant differences in major
bleeding events between the ID and UW groups in our
study. Patients in the UW group were associated with a
statistically non-significant trend towards increased pocket
hematoma formation compared to the ID cohort. This
is an interesting finding since an increased risk of pocket
hematoma development has been linked to the use of
agents with short half-lives in prior studies when compared
to an UW strategy. Incidence of pocket hematoma while
on an UW strategy in this study was consistent with a
previous well-constructed small randomized trial (23). The
increased bleeding trends in pocket hematomas in the UW
may be due to the fact that patients are no longer fully
anticoagulated at the time of implant in the ID group but

© Cardiovascular Diagnosis and Therapy. All rights reserved.

remain therapeutically anticoagulated in the UW group.
A similar study performed by Kosiuk et al. confirmed our
findings and showed a statistically non-significant trend
toward reduced number of pocket hematomas with ID
use compared to UW in patients receiving implantable
devices (17). This study adds to the current body of
literature suggesting this latter finding of reduced bleeding
trends in ID group versus UW groups.
The primary goal in choosing an appropriate perioperative
anticoagulation regimen is to prevent embolic events and
reduce bleeding complications. Our results revealed no
thromboembolic events in either group although this study
was not powered to show differences in this outcome.
One would expect that an uninterrupted anticoagulation
strategy would reduce thromboembolic events better than
an interrupted strategy, therefore favoring UW over ID. In
our ID group, the mean time off dabigatran was 23.3 hours
and the mean time to resume the dose was 21.0 hours
post-procedure. One would expect most cardioembolic
events would occur if anticoagulation were to be held
for more than 48 hours. Since the half-life of dabigatran
is 12-17 hours in patients with preserved renal function,
one could postulate that withholding one or two doses of
dabigatran would mean that a patient would remain not

www.thecdt.org
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anticoagulated for less than the 48 hours window where the
risk of clot formation is low and thus represent a reasonable
perioperative bridging strategy.
It is still unknown whether uninterrupted dabigatran
would be a viable option for patients undergoing implantable
cardiac devices. The lack of a reversal agent makes this
option less attractive and difficult to study. Perhaps in the
future, once reversal agents become available, this strategy
could be employed and formally studied in a large cohort
study.
Our data support the use of ID as a reasonable strategy
of treating patients undergoing cardiac device implantation.
The results suggest that ID is at least as safe as continued
warfarin in regards to bleeding. Though thromboembolic
events were not different between the two groups, a large
randomized trial powered to show those differences is
needed. Survey data collected by Nascimento et al. has
been useful in describing utilization and prescribing
patterns of perioperative dabigatran use alongside other
new oral anticoagulants among multiple centers in a
large population (18). However, inter-center variability
in anticoagulation stop and restart times limits accurate
assessment of safety and efficacy outcomes. This highlights
the need for a large randomized control trial to guide
further therapy in this cohort of patients.
This study adds to the current literature regarding
anticoagulation with dabigatran and can be utilized for
future large-scale investigations.

Madan et al. Warfarin vs . dabigatran in implantable cardiac devices

this difference was not statistically significant. A large
multicenter randomized trial is needed in order to
definitively investigate any differences in thromboembolic
events between these two strategies.
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